Manages pain severe enough to require an opioid analgesic. ANDA 210506, held by Ascent Pharms Inc. Hydromorphone Hydrochloride.
As of Nov 16, 2026, ANDA 210506 (Hydromorphone Hydrochloride), held by Ascent Pharms Inc, was first approved by FDA on Jan 17, 2018, with 3 approved supplements and 0 published complete response letters.
Hydromorphone Hydrochloride Tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve Hydromorphone Hydrochloride Tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 17, 2018 | Original application | Approved |
| Hydromorphone Hydrochloride2MG · tablet;oral | Hydromorphone Hydrochloride | Rx |
| Hydromorphone Hydrochloride4MG · tablet;oral | Hydromorphone Hydrochloride | Rx |
| Hydromorphone Hydrochloride8MG · tablet;oral | Hydromorphone Hydrochloride | Rx |
| Jun 18, 2026 | Supplement 7REMS | Approved | None posted |
| Oct 31, 2024 | Supplement 3REMS | Approved | None posted |
| Sep 18, 2018 | Supplement 2REMS | Approved | None posted |
| Jan 17, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters